Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + R-CHOP in Untreated High-Risk Non-GCB DLBCL
NCT03995147Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Aug 2019
- Primary completion
- Feb 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University of Chicago. Started Aug 2019; status: active, not recruiting.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03995147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03995147.